Thyrotropinoma - the case report about one of the rarest type of pituitary adenomas
DOI:
https://doi.org/10.12775/JEHS.2022.12.04.002Keywords
thyrotropinoma, secondary hyperthyroidism, somatostatin analogue, case reportAbstract
Pituitary tumours are a significant diagnostic problem in clinical practice. Considering all the rarity of thyrotropic hormone secreting adenoma it is a diagnostic and therapeutic challenge in part due to the lack of the preoperative standards. TSH-oma, besides hyperthyroidism symptoms, might be a cause of other endocrine disorders, most often dysfunction of other tropic axes and may cause neurological symptoms associated with sella expansion. We report a case of a 49-year-old male patient with macroadenoma, overt clinical hyperthyroidism, secondary adrenal insufficiency and hypogonadotropic hypogonadism. The diagnosis of thyrotropinoma was confirmed by blood tests that revealed elevated FT3 and FT4 levels together with high TSH. Thyrotropin-releasing hormone (TRH) test was performed and magnetic resonance imaging (MRI) imaging revealed the presence of macroadenoma. Histopathology examination confirmed the diagnosis of thyrotropic cell pituitary adenoma. The appropriate therapy for thyrotropin pituitary adenoma has not been elaborated in reports of this domain. Preoperatively the patient was prepared by long-acting somatostatin analogue (Sandostatin LAR) injections to reduce tumor size with good therapeutic effect afterwards underwent surgical transsphenoidal treatment successfully. However, specific treatment guidelines for pituitary thyrotropic tumors need to be elaborated more in details.
References
Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta neuropathologica [Internet]. 2017 Oct 1 [cited 2021 Nov 4];134(4):521–35. Available from: https://pubmed.ncbi.nlm.nih.gov/28821944/
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA [Internet]. 2017 Feb 7 [cited 2021 Nov 4];317(5):516–24. Available from: https://pubmed.ncbi.nlm.nih.gov/28170483/
The Epidemiology of Pituitary Adenomas - ClinicalKey [Internet]. [cited 2021 Nov 4]. Available from: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0889852920300256?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0889852920300256%3Fshowall%3Dtrue&referrer=https:%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
Luo P, Zhang L, Yang L, An Z, Tan H. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor. Frontiers in Endocrinology. 2020 Nov 27;11.
Diagnosis and treatment of pituitary adenomas - PubMed [Internet]. [cited 2021 Nov 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/15765032/
Thyrotropin-secreting pituitary adenomas: biological and molecular features, diagnosis and therapy - PubMed [Internet]. [cited 2021 Nov 4]. Available from: https://pubmed.ncbi.nlm.nih.gov/18923369/
Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, et al. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary [Internet]. 2016 Apr 1 [cited 2021 Nov 4];19(2):183–93. Available from: https://pubmed.ncbi.nlm.nih.gov/26689573/
Losa M, Fortunato M, Molteni L, Pereiti E, Mortini P. Thyrotropin-secreting pituitary adenomas: Biological and molecular features, diagnosis and therapy. Minerva Endocrinologica [Internet]. 2008 Dec [cited 2021 Nov 4];33(4):329–40. Available from: https://neuro.unboundmedicine.com/medline/citation/18923369/Thyrotropin_secreting_pituitary_adenomas:_biological_and_molecular_features_diagnosis_and_therapy_
Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas. The Journal of clinical endocrinology and metabolism [Internet]. 2000 May 1 [cited 2021 Nov 4];85(5):1789–93. Available from: https://pubmed.ncbi.nlm.nih.gov/10843153/
Lake MG, Krook LS, Cruz S v. Pituitary Adenomas: An Overview. American Family Physician [Internet]. 2013 Sep 1 [cited 2021 Nov 4];88(5):319–27. Available from: www.aafp.org/afp
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. Endotext [Internet]. 2019 Jan 11 [cited 2021 Nov 4]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK278978/
Beck-Peccoz P, Persani L, Lania A. Thyrotropin-Secreting Pituitary Adenomas. Endotext [Internet]. 2019 Jan 11 [cited 2021 Nov 4]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK278978/
Aron DC, Tyrrell JB, Wilson CB. Pituitary tumors. Current concepts in diagnosis and management. Western Journal of Medicine [Internet]. 1995 [cited 2021 Nov 5];162(4):340. Available from: /pmc/articles/PMC1022773/?report=abstract
FAGLIA G. The Clinical Impact of the Thyrotropin-Releasing Hormone Test. Thyroid. 1998 Oct;8(10):903–8.
Erem C, Hacihasanoglu A, Sari A, Ersöz HÖ, Ukinç K, Fidan S. A rare case and a rapid tumor response to therapy. Endocrine 2004 25:2 [Internet]. 2004 [cited 2021 Nov 5];25(2):141–5. Available from: https://link.springer.com/article/10.1385/ENDO:25:2:141
Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. European Journal of Endocrinology [Internet]. 2007 Jul 1 [cited 2021 Nov 5];157(1):39–46. Available from: https://eje.bioscientifica.com/view/journals/eje/157/1/1570039.xml
van Varsseveld NC, Bisschop PHLT, Biermasz NR, Pereira AM, Fliers E, Drent ML. A long-term follow-up study of eighteen patients with thyrotrophin-secreting pituitary adenomas. Clinical endocrinology [Internet]. 2014 Mar [cited 2021 Nov 5];80(3):395–402. Available from: https://pubmed.ncbi.nlm.nih.gov/23848527/
Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. European Journal of Endocrinology [Internet]. 2003 Apr 1 [cited 2021 Nov 5];148(4):433–42. Available from: https://eje.bioscientifica.com/view/journals/eje/148/4/433.xml
Byun J, Kim JH, Kim YH, Cho YH, Hong SH, Kim CJ. Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas : Single Institutional Experience of 14 Consecutive Cases. Journal of Korean Neurosurgical Society [Internet]. 2020 [cited 2021 Nov 5];63(4):495–503. Available from: http://www.jkns.or.kr/journal/view.php?doi=10.3340/jkns.2019.0169
Erem C, Hacihasanoglu A, Sari A, Ersöz HÖ, Ukinç K, Fidan S. A Rare Case and a Rapid Tumor Response to Therapy: Dramatic Reduction in Tumor Size During Octreotide Treatment in a Patient with TSH-Secreting Pituitary Macroadenoma. Endocrine [Internet]. [cited 2021 Nov 5];25(2):141–6. Available from: https://www.academia.edu/23336047/A_Rare_Case_and_a_Rapid_Tumor_Response_to_Therapy_Dramatic_Reduction_in_Tumor_Size_During_Octreotide_Treatment_in_a_Patient_with_TSH_Secreting_Pituitary_Macroadenoma
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Piotr Michał Jarosz, Zuzanna Idzik; Jakub Gołacki, Ewa Obel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 536
Number of citations: 0
